Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Calcium prevents loss of glutathione and reduces oxidative stress upon reperfusion in the perfused liver
Here's the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations
Sirt1-mediated deacetylation of PGC-1 alleviated hepatic steatosis in type 2 diabetes mellitus via improving mitochondrial fatty acid oxidation
Tanaka, T
US$ 24.88
US$ 22.32
US$ 29.62
US$ 21.75
